The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Pluripotent stem cell-derived hepatocyte-like cells
Open accessAbstract
Liver disease is an important clinical problem, impacting over 30 million Americans and over 600 million people worldwide. It is the 12th leading cause of death in the United States and the 16th worldwide. Due to a paucity of donor organs, several thousand Americans die yearly while waiting for liver transplantation. Unfortunately, alternative tissue sources such as fetal hepatocytes and hepatic cell lines are unreliable, difficult to reproduce, and do not fully recapitulate hepatocyte phenotype and function. As a consequence, alternative cell sources that do not have these limitations have been sought. Human embryonic stem (hES) cell- and induced pluripotent stem (iPS) cell-derived hepatocyte-like cells may enable cell based therapeutics, the study of the mechanisms of human disease and human development, and provide a platform for pharmacology and toxicology drug screening. iPS cells can be differentiated in a stepwise fashion with high efficiency and reproducibility into hepatocyte-like cells that exhibit morphologic and phenotypic characteristics of hepatocytes. In addition, iPS-derived hepatocyte-like cells possess some functional hepatic activity as they secrete urea, alpha-1-antitrypsin, and albumin. However, the combined phenotypic and functional traits exhibited by iPS-derived hepatocyte-like cells resemble a relatively immature hepatic phenotype that more closely resembles that of fetal hepatocytes rather than adult hepatocytes. Specifically, iPS-derived hepatocyte-like cells express fetal markers such as alpha fetoprotein and lack key mature hepatocyte functions, as reflected by drastically reduced activity (0.1%) of many detoxification enzymes (i.e. CYP2A6, CYP3A4). These key differences between iPS-derived hepatocyte-like cells and adult hepatocytes have limited the use of stem cells as a renewable source of functional adult human hepatocytes for in vitro and in vivo applications. Unfortunately, the developmental pathways that control hepatocyte maturation from a fetal into an adult hepatocyte are poorly understood, which has hampered the field in its efforts to induce further maturation of iPS-derived hepatic lineage cells. This review analyzes recent developments in the derivation of hepatocyte-like cells, and proposes important points to consider and assays to perform during their characterization. In the future, we envision that iPS-derived hepatocyte-like cells will be used as in vitro models of human disease, and in the longer term, provide an alternative cell source for drug testing and clinical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · Nephron · doi:10.1159/000433566 · Cited by 3,515
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754
Complete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 2×
“Although in vitro function was similar to prior monolayer studies anddidnot demonstrate enhanceddifferentiated function as compared to primary adult human hepatocytes, these gel-incorporated cell clusters enabled transplantation, engraftment, vascularization and functional activity in vivo (Takebe et al., 2013).”
Animal models of human disease: zebrafish swim into view
Lieschke, G. J., & Currie, P. D. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2091 · Cited by 2,167
Research works printed but not linked: 4
- Lavon, 2010, Generation of hepatocytes from human embryonic stem cells, Methods Mol Biol, 640, 237, 10.1007/978-1-60761-688-7_11 · DOI
- Murray, 2011, Heterogeneous accumulation of fluorescent bile acids in primary rat hepatocytes does not correlate with their homogenous expression of ntcp, Am J Physiol Gastrointest Liver Physiol, 301, G60, 10.1152/ajpgi.00035.2011 · doi:10.1152/ajpgi.00035.2011
- Pillai, 2013, A sensitive and specific CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS, J Pharmaceutical Biomed Anal, 74, 126, 10.1016/j.jpba.2012.10.016 · doi:10.1016/j.jpba.2012.10.016
- Ubeaud, 2001, Comparison of the stability of some major cytochrome P450 and conjugation reactions in rat, dog and human hepatocyte monolayers, European J Drug Metab Pharmacokinetics, 26, 37, 10.1007/BF03190374 · doi:10.1007/bf03190374
Cited by
Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Self-citationShlomai, A., Schwartz, R. E., Ramanan, V., Bhatta, A., de Jong, Y. P., Bhatia, S. N., & Rice, C. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412631111 · Cited by 258
Self-citationGuidelines for genetic studies in single patients: lessons from primary immunodeficiencies
Casanova, J.-L., Conley, M. E., Seligman, S. J., Abel, L., & Notarangelo, L. D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140520 · Cited by 257
Lauschke, V. M., Hendriks, D. F. G., Bell, C. C., Andersson, T. B., & Ingelman-Sundberg, M. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00150 · Cited by 241
Wang, Y., Wang, H., Deng, P., Chen, W., Guo, Y., Tao, T., & Qin, J. (2018) · Lab on a Chip · doi:10.1039/c8lc00869h · Cited by 222
Lauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Ma, C., Zhao, L., Zhou, E.-M., Xu, J., Shen, S., & Wang, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03869 · Cited by 145
Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Evaluation of hepatotoxicity using multiparameter cell feature analysis measured by fluorescent imaging was implemented by O’Brien et al.181 using HepG2 and was later extended by Xu et al.180 to short-term ECM sandwich cultures of PHHs.”
BackgroundMethodInfluentialSelf-citationModeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
Human Organoids for Predictive Toxicology Research and Drug Development
Matsui, T., & Shinozawa, T. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767621 · Cited by 109
Carpentier, A., Nimgaonkar, I., Chu, V., Xia, Y., Hu, Z., & Liang, T. J. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.03.009 · Cited by 90
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“Protocols to differentiate iPSCs into hepatocyte-like cells (iPSC-HHs) use growth factors inspired from embryology; however, liver functions remain very low (<10%) relative to adult PHHs [26].”
BackgroundSelf-citationImmune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87
“The use of human induced pluripotent stem cell for derivation of hepatocyte-like cells represents another option despite remaining suboptimal, because cells are not fully metabolically competent and show very low levels of activity of the metabolizing enzymes [129,130].”
BackgroundZhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Garnier, D., Li, R., Delbos, F., Fourrier, A., Collet, C., Guguen-Guillouzo, C., Chesné, C., & Nguyen, T. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-26584-1 · Cited by 71
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Peters, D. T., Henderson, C. A., Warren, C. R., Friesen, M., Xia, F., Becker, C. E., Musunuru, K., & Cowan, C. A. (2016) · Development · doi:10.1242/dev.132209 · Cited by 68
Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine
Huang, D. (., Gibeley, S. B., Xu, C., Xiao, Y., Celik, O., Ginsberg, H. N., & Leong, K. W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909553 · Cited by 65
Kammerer, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910214 · Cited by 59
Potential of human induced pluripotent stem cells in studies of liver disease
Sampaziotis, F., Segeritz, C., & Vallier, L. (2015) · Hepatology · doi:10.1002/hep.27651 · Cited by 49
“Indeed, cirrhosis/fibrosis secondary to certain etiologies, such as congestive cardiac failure, can prove challenging to model, especially in a culture system with a short halflife.(10) Furthermore, the impact of the fetal phenotype of HLCs for such platforms remains unclear.”
BackgroundGao, X., Li, R., Cahan, P., Zhao, Y., Yourick, J. J., & Sprando, R. L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01914-1 · Cited by 40
Peptide-based scaffolds for the culture and maintenance of primary human hepatocytes
MacPherson, D., Bram, Y., Park, J., & Schwartz, R. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-86016-5 · Cited by 36
Self-citationGuo, L., Karoubi, G., Duchesneau, P., Shutova, M. V., Sung, H.-K., Tonge, P., Bear, C., Rogers, I., Nagy, A., & Waddell, T. K. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.022 · Cited by 33
Wang, Y., Lee, J.-H., Shirahama, H., Seo, J., Glenn, J. S., & Cho, N.-J. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00487 · Cited by 21
Sanal, M. G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i21.6427 · Cited by 10
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
Kong, D., Yu, S., Heegsma, J., Blokzijl, T., Qin, T., Pan, Y., Blokzijl, H., de Meijer, V. E., Duan, Y., Faber, K. N., et al. (2026) · Journal of nanobiotechnology · doi:10.1186/s12951-026-04477-0 · Cited by 4
Metadata
- Authors
- Schwartz, R. E., Fleming, H. E., Khetani, S. R., & Bhatia, S. N.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 32
- Issue
- 2
- Pages
- 504-513
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2013620034
- Cited by
- 282
- References
- 92
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- NIH Roadmap for Medical Research Grant (1 R01 DK085713-01)
- AGA Research Scholar Award
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.